Altimmune, Inc. (ALT) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
Sector
Healthcare
Industry
Biotechnology
Result
Pass
Reason
The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
Debt Ratio
Value: 5.1% | Threshold: 30% | Result: Pass
Cash & Interest-bearing Securities Ratio
Value: 46.5% | Threshold: 30% | Result: Fail
Non-Permissible Income Ratio
Value: 18392.7% | Threshold: 5% | Result: Fail
Dividend Purification
Purification percentage: 100.00%.Based on the company's financial statements, approximately 100.00% of dividend income should be donated to charity for purification. This is derived from identified interest income (18392.68% of total income). Some scholars may differ on the exact calculation method.
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Frequently Asked Questions
Is Altimmune, Inc. (ALT) stock halal to invest in?
According to AAOIFI Shariah screening standards, Altimmune, Inc. (ALT) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Does Altimmune, Inc. have any interest income?
Altimmune, Inc.'s interest income ratio is 46.5% of total revenue. AAOIFI standards require this to be below 30%.
What guidelines are used to determine if ALT stock is Shariah-compliant?
Based on the company's financial statements, approximately 100.00% of dividend income should be donated to charity for purification. This is derived from identified interest income (18392.68% of total income). Some scholars may differ on the exact calculation method.
Uses quarterly data
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
United StatesNASDAQHealthcare
Screened using AAOIFI Standard No. 21 on October 20, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.
Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.
Verdict history
Free with an account.
No verdict changes recorded since first screened on Jul 28, 2026. We started recording changes on Oct 19, 2026.
Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.
Get More on the Mizaan App
Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.
Frequently Asked Questions
According to AAOIFI Shariah screening standards, Altimmune, Inc. (ALT) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Altimmune, Inc.'s interest income ratio is 46.5% of total revenue. AAOIFI standards require this to be below 30%.
ALT is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
Altimmune, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
You can save ALT to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Dividends from Altimmune, Inc. require purification. Approximately 100.00% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
ALT is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
How often is Altimmune, Inc. stock reviewed for Shariah compliance?
Altimmune, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
How can I stay updated on Altimmune, Inc.'s compliance status?
You can save ALT to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Are dividends from Altimmune, Inc. stock considered halal?
Dividends from Altimmune, Inc. require purification. Approximately 100.00% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Do I need to pay Zakat on my Altimmune, Inc. shares?
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
